Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07662213 · ClinicalTrials.gov registry record · Phase 3
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by AstraZeneca.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,200
- Enrollment target
NCT07662213 is a Phase 3 study that has not yet begun recruiting, run by AstraZeneca. The registered enrollment target is 1,200 participants.
The verdict
NCT07662213, a Phase 3 study, has not yet begun recruiting, sponsored by AstraZeneca.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,200 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
Interventions
- DRUG Semaglutide
- DRUG Elecoglipron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,200 participants |
| Start Date | 2026-07-06 |
| Est. Completion | 2028-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07662213
The ClinicalTrials.gov registry entry for NCT07662213 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 1,200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT07662213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07662213 about?
NCT07662213 is a clinical study titled "A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus". The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with T2DM and increased cardiovascular risk that is inadequately managed alone or on stable treatment with other background glucose-lowering medication(s).
What is the current status of trial NCT07662213?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,200 participants. The study started on 2026-07-06. Estimated completion is 2028-05-23.
What interventions are being tested in trial NCT07662213?
The interventions under investigation include: Semaglutide (DRUG), Elecoglipron (DRUG).
Who is sponsoring clinical trial NCT07662213?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.